These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dysregulation of proinflammatory versus anti-inflammatory human T Noster R; de Koning HD; Maier E; Prelog M; Lainka E; Zielinski CE J Allergy Clin Immunol; 2016 Oct; 138(4):1161-1169.e6. PubMed ID: 27040374 [TBL] [Abstract][Full Text] [Related]
24. Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes. Xiao F; Wu L; Zhu X; Zhang L; Liu D; Wu L; Zou H; Lu L Rheumatol Immunol Res; 2022 Mar; 3(1):11-16. PubMed ID: 35772080 [TBL] [Abstract][Full Text] [Related]
25. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158 [TBL] [Abstract][Full Text] [Related]
26. [Proinflammatory cytokines and cardio-vascular risk: From myocardial infarction tocytokine storm of COVID-19]. Miossec P Bull Acad Natl Med; 2021 Jan; 205(1):43-48. PubMed ID: 33199926 [TBL] [Abstract][Full Text] [Related]
27. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide. Wang Z; Wang Y; Vilekar P; Yang SP; Gupta M; Oh MI; Meek A; Doyle L; Villar L; Brennecke A; Liyanage I; Reed M; Barden C; Weaver DF PeerJ; 2020; 8():e9533. PubMed ID: 32704455 [TBL] [Abstract][Full Text] [Related]
28. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052 [TBL] [Abstract][Full Text] [Related]
29. Multiple Peaked Cytokine Storm: Is Multiple Exposures to the COVID-19 Virus a Possible Cause? Kumar A; Kumar A; Kumar A; Kumar N; Sinha C; Singh V Indian J Crit Care Med; 2021 Apr; 25(4):463-464. PubMed ID: 34045815 [TBL] [Abstract][Full Text] [Related]
31. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616 [TBL] [Abstract][Full Text] [Related]
32. Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease. Mudd PA; Crawford JC; Turner JS; Souquette A; Reynolds D; Bender D; Bosanquet JP; Anand NJ; Striker DA; Martin RS; Boon ACM; House SL; Remy KE; Hotchkiss RS; Presti RM; OHalloran JA; Powderly WG; Thomas PG; Ellebedy AH medRxiv; 2020 May; ():. PubMed ID: 32511543 [TBL] [Abstract][Full Text] [Related]
33. Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19. Ravichandran S; Manickam N; Kandasamy M Med Drug Discov; 2022 Sep; 15():100136. PubMed ID: 35721801 [TBL] [Abstract][Full Text] [Related]
34. Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. Kaffash Farkhad N; Reihani H; Sedaghat A; Moghadam AA; Moghadam AB; Tavakol-Afshari J Regen Ther; 2021 Dec; 18():152-160. PubMed ID: 34124322 [TBL] [Abstract][Full Text] [Related]
35. The Protective Role of IL-17 and IL-22 in COVID-19 Infection. Aksakal S; Gorgun S Iran J Immunol; 2024 Jun; 21(3):225-233. PubMed ID: 38920022 [TBL] [Abstract][Full Text] [Related]
36. Immunomodulating Phytochemicals: An Insight Into Their Potential Use in Cytokine Storm Situations. Alarabei AA; Abd Aziz NAL; Ab Razak NI; Abas R; Bahari H; Abdullah MA; Hussain MK; Abdul Majid AMS; Basir R Adv Pharm Bull; 2024 Mar; 14(1):105-119. PubMed ID: 38585461 [TBL] [Abstract][Full Text] [Related]
37. Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review. Fan Y; Wang Y; Yu S; Chang J; Yan Y; Wang Y; Bian Y Chin Med; 2021 Jul; 16(1):67. PubMed ID: 34321065 [TBL] [Abstract][Full Text] [Related]
38. Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19. Zou Y; Meng Z J Inflamm Res; 2021; 14():5611-5618. PubMed ID: 34754211 [TBL] [Abstract][Full Text] [Related]
39. Baicalein self-microemulsion based on drug-phospholipid complex for the alleviation of cytokine storm. Liao H; Ye J; Gao Y; Lian C; Liu L; Xu X; Feng Y; Yang Y; Yang Y; Shen Q; Gao L; Liu Z; Liu Y Bioeng Transl Med; 2023 Jan; 8(1):e10357. PubMed ID: 36684101 [TBL] [Abstract][Full Text] [Related]
40. Nanomedicine approaches to reduce cytokine storms in severe infections. Ahmar Rauf M; Nisar M; Abdelhady H; Gavande N; Iyer AK Drug Discov Today; 2022 Nov; 27(11):103355. PubMed ID: 36099962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]